Inclusion Criteria:
* Age: 18-80 years of age.
Diagnosis and Anatomical Suitability:
Subacute or chronic aortic arch dissection requiring intervention, where the proximal end of the stent graft requires anchoring in Zone 0, and meets the following vascular anatomical criteria:
Ascending aorta (may include graft segments) ≥ 40 mm in length (measured from the sinotubular junction to the proximal edge of the IA along the centerline).
Proximal landing zone diameter ≥ 24 mm and ≤ 47 mm. Proximal landing zone length ≥ 20 mm. Diameters of the IA, LCCA, and LSA ≤ 24 mm and ≥ 6 mm, with lengths ≥ 20 mm. Suitable arterial access for endovascular intervention. Informed Consent: Capable of understanding the study purpose, voluntarily agreeing to participate, and providing written informed consent (by the subject or their legal representative). Willing to comply with follow-up requirements per the protocol.
Surgical Risk Assessment: Deemed high surgical risk (evaluated by at least two independent vascular or cardiac surgeons) or confirmed to have significant contraindications to open surgery.
Exclusion Criteria:
* Prior aortic intervention: History of open or endovascular repair of the descending or abdominal aorta.
Concurrent AAA requiring intervention: Coexisting abdominal aortic aneurysm requiring surgical intervention within 30 days.
Specific aortic pathologies: infectious aortitis, Takayasu arteritis, Marfan syndrome, or other connective tissue disorders.
Active systemic infection: Ongoing systemic infection or high risk of systemic infection.
Severe arch vessel disease: Severe stenosis, calcification, thrombosis, or tortuosity of the IA, LCCA, or LSA.
Acute ischemia: Bowel necrosis or lower limb ischemic necrosis. Pre-existing paraplegia. Post-cardiac transplant status. Recent cardiovascular events: Myocardial infarction or stroke within the past 3 months.
Advanced heart failure: NYHA Class IV or left ventricular ejection fraction (LVEF) \<30%.
Active gastrointestinal bleeding: Active peptic ulcer or upper gastrointestinal bleeding within the past 3 months.
Hematologic abnormalities: Leukopenia (WBC \< 3×10⁹/L), Anemia (Hb \< 90 g/L), Coagulopathy, Thrombocytopenia (platelets \< 50×10⁹/L).
Renal insufficiency: Serum creatinine \> 221 μmol/L (2.5 mg/dL) or end-stage renal disease requiring dialysis (investigator discretion).
Severe hepatic dysfunction: ALT/AST \> 5× upper limit of normal (ULN), Serum total bilirubin (STB) \> 2× ULN.
High-risk intracranial lesions (any of the following):
1. Unruptured aneurysm ≥7 mm (anterior circulation) or ≥5 mm (posterior circulation)
2. Prior rupture or high-risk morphology (daughter sac, aspect ratio \>1.6)
3. Intracranial arterial stenosis ≥50% with poor collateral flow. Contrast allergy. Pregnancy or lactation. Anesthesia/surgery contraindications: Severe comorbidities precluding tolerance to anesthesia or surgery.
Life expectancy \< 12 months. Current participation in other drug or device clinical trials. Other exclusions: Any conditions deemed unsuitable for participation by the investigator.
